Mechanism of Toxicity in Rotenone Models of Parkinson's Disease

Journal of Neuroscience

Volumn 23, Issue 34, 2003, Pages 10756-10764

  Sherer, Todd B ^a   Betarbet, Ranjita ^a   Testa, Claudia M ^a   Seo, Byoung Boo ^c   Richardson, Jason R ^a,b   Kim, Jin Ho ^d   Miller, Gary W ^a,b   Yagi, Takao ^c   Matsuno Yagi, Akemi ^c   Greenamyre, J Timothy ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d Chosun University   (South Korea)

Author keywords

Dopamine; Mitochondria; NADH dehydrogenase; Organotypic; Oxidative stress; tocopherol

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALPHA SYNUCLEIN; ALPHA TOCOPHEROL; ANTIOXIDANT; DEOXYGLUCOSE; PESTICIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); ROTENONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOENERGY; BRAIN MITOCHONDRION; CELL DEATH; CELL INCLUSION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; ENZYME INHIBITION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MESENCEPHALON; NERVE DEGENERATION; NEWBORN; NONHUMAN; OLFACTORY BULB; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

EID: 0344198025     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.23-34-10756.2003     Document Type: Article

References (52)

1. Alam A, Schmidt WJ (2002) Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. Behav Brain Res 136.
2. Alam ZI, Daniel SE, Lees AJ, Marsden DC, Jenner P, Halliwell B (1997) A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J Neurochem 69:1326-1329.
3. Bai Y, Hajek P, Chomyn A, Chan E, Seo BB, Matsuno-Yagi A, Yagi T, Attardi G (2001) Lack of complex I activity in human cells carrying a mutation in MtDNA-encoded ND4 subunit is corrected by the Saccharomyces cerevisiae NADH-quinone oxidoreductase (NDI1) gene. J Biol Chem 276:38808-38813.
4. Barrientos A, Moraes CT (1999) Titrating the effects of mitochondrial complex I impairment in the cell physiology. J Biol Chem 274:16188-16197.
5. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3:1301-1306.
6. Betarbet R, Sherer TB, Kim JH, Baptista M, Cookson MR, Greenamyre JT (2002) Rotenone models of Parkinson's disease: altered alpha-synuclein expression following chronic inhibition of complex I. Soc Neurosci Abstr 386.316.
7. Cardellach F, Marti MJ, Fernandez-Sola J, Marin C, Hoek JB, Tolosa E, Urbano-Marquez A (1993) Mitochondrial respiratory chain activity in skeletal muscle from patients with Parkinson's disease. Neurology 43:2258-2262.
8. Cassarino DS, Fall CP, Swerdlow RH, Smith TS, Halvorsen EM, Miller SW, Parks JP, Parker Jr WD, Bennett Jr JP (1997) Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease. Biochim Biophys Acta 1362:77-86.
9. Choi J, Conrad CC, Dai R, Malakowsky CA, Talent JA, Carroll CA, Weintraub ST, Gracy RW (2003) Vitamin E prevents oxidation of antiapoptotic proteins in neuronal cells. Proteomics 3:73-77.
10. Cormier A, Morin C, Zini R, Tillement JP, Lagrue G (2003) Nicotine protects rat brain mitochondria against experimental injuries. Neuropharmacology 44:642-652.
11. Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, Marsden CD (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 52:381-389.
12. Floor E, Wetzel MG (1998) Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J Neurochem 70:268-275.
13. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, Lee VM (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290:985-989.
14. Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Richardson RJ (1998) The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology 50:1346-1350.
15. Haas RH, Nasirian F, Nakano K, Ward D, Pay M, Hill R, Shults CW (1995) Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann Neurol 37:714-722.
16. Hastings TG, Lewis DA, Zigmond MJ (1996) Reactive dopamine metabolites and neurotoxicity: implications for Parkinson's disease. Adv Exp Med Biol 387:97-106.
17. Hensley K, Pye QN, Maidt ML, Stewart CA, Robinson KA, Jaffrey F, Floyd RA (1998) Interaction of alpha-phenyl-N-tert-butyl nitrone and alternative electron acceptors with complex I indicates a substrate reduction site upstream from the rotenone binding site. J Neurochem 71:2549-2557.
18. Höglinger GU, Feger J, Prigent A, Michel PP, Parain K, Champy P, Ruberg M, Oertel WH, Hirsch EC (2003) Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. J Neurochem 84:491-502.
19. Hsu LJ, Sagara Y, Arroyo A, Rockenstein E, Sisk A, Mallory M, Wong J, Takenouchi T, Hashimoto M, Masliah E (2000) alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol 157:401-410.
20. Jenner P (1998) Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov Disord 13:24-34.
21. Jha N, Jurma O, Lalli G, Liu Y, Pettus EH, Greenamyre JT, Liu RM, Forman HJ, Andersen JK (2000) Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity. Implications for Parkinson's disease. J Biol Chem 275:26096-26101.
22. Kanda S, Bishop JF, Eglitis MA, Yang Y, Mouradian MM (2000) Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation. Neuroscience 97:279-284.
23. Ko L, Mehta ND, Farrer M, Easson C, Hussey J, Yen S, Hardy J, Yen SH (2000) Sensitization of neuronal cells to oxidative stress with mutated human alpha-synuclein. J Neurochem 75:2546-2554.
24. Krishnan S, Chi EY, Wood SJ, Kendrick BS, Li C, Garzon-Rodriguez W, Wypych J, Randolph TW, Narhi LO, Biere AL, Citron M, Carpenter JF (2003) Oxidative dimer formation is the critical rate-limiting step for Parkinson's disease alpha-synuclein fibrillogenesis. Biochemistry 42:829-837.
25. + oxidation-reduction state. Biochem J 368:545-553.
26. Lee HJ, Shin SY, Choi C, Lee YH, Lee SJ (2001) Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors. J Biol Chem 27:27.
27. Maker HS, Weiss C, Silides DJ, Cohen G (1981) Coupling of dopamine oxidation (monoamine oxidase activity) to glutathione oxidation via the generation of hydrogen peroxide in rat brain homogenates. J Neurochem 36:589-593.
28. Matthews RT, Klivenyi P, Mueller G, Yang L, Wermer M, Thomas CE, Beal MF (1999) Novel free radical spin traps protect against malonate and MPTP neurotoxicity. Exp Neurol 157:120-126.
29. McCormack AL, Thiruchelvam M, Manning-Bog AB, Thiffault C, Langston JW, Cory-Slechta DA, Di Monte DA (2002) Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis 10:119-127.
30. Menegon A, Board PG, Blackburn AC, Mellick GD, Le Couteur DG (1998) Parkinson's disease, pesticides, and glutathione transferase polymorphisms. Lancet 352:1344-1346.
31. Mizuno Y, Ohta S, Tanaka M, Takamiya S, Suzuki K, Sato T, Oya H, Ozawa T, Kagawa Y (1989) Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem Biophys Res Commun 163:1450-1455.
32. Mollace V, Iannone M, Muscoli C, Palma E, Granato T, Rispoli V, Nistico R, Rotiroti D, Salvemini D (2003) The role of oxidative stress in paraquat-induced neurotoxicity in rats: protection by non peptidyl superoxide dismutase mimetic. Neurosci Lett 335:163-166.
33. Nicklas WJ, Vyas I, Heikkila RE (1985) Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci 36:2503-2508.
34. Parker Jr WD, Boyson SJ, Parks JK (1989) Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 26:719-723.
35. Parkinson Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 328:176-183.
36. Pearce RK, Owen A, Daniel S, Jenner P, Marsden CD (1997) Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J Neural Transm 104:661-677.
37. Roghani M, Behzadi G (2001) Neuroprotective effect of vitamin E on the early model of Parkinson's disease in rat: behavioral and histochemical evidence. Brain Res 892:211-217.
38. Schapira AH (1999) Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia. Biochim Biophys Acta 1410:159-170.
39. Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD (1989) Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1:1269.
40. Seo BB, Wang J, Flotte TR, Yagi T, Matsuno-Yagi A (2000) Use of the NADH-quinone oxidoreductase (NDI1) gene of Saccharomyces cerevisiae as a possible cure for complex I defects in human cells. J Biol Chem 275:37774-37778.
41. Seo BB, Nakamaru-Ogiso E, Flotte TR, Yagi T, Matsuno-Yagi A (2002) A single-subunit NADH-quinone oxidoreductase renders resistance to mammalian nerve cells against complex I inhibition. Mol Ther 6:336-341.
42. Sherer TB, Betarbet R, Greenamyre JT (2001) The rotenone model of Parkinson's disease in vivo: selective striatal oxidative damage and caspase-3 activation in nigrostriatal neurons. Soc Neurosci Abstr 27:653.2.
43. Sherer TB, Betarbet R, Greenamyre JT (2002a) Environment, mitochondria, and Parkinson's disease. Neuroscientist 8:192-197.
44. Sherer TB, Betarbet R, Stout AK, Lund S, Baptista M, Panov AV, Cookson MR, Greenamyre JT (2002b) An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered α-synuclein metabolism and oxidative damage. J Neurosci 22:7006-7015.
45. Sherer TB, Kim JH, Betarbet R, Greenamyre JT (2003) Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp Neurol 179:9-16.
46. Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, Lew M (2002) Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 59:1541-1550.
47. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature 388:839-840.
48. Spina MB, Cohen G (1988) Exposure of striatal synaptosomes to L-dopa increases levels of oxidized glutathione. J Pharmacol Exp Ther 247:502-507.
49. Stoppini L, Buchs PA, Muller D (1991) A simple method for organotypic cultures of nervous tissue. J Neurosci Methods 37:173-182.
50. Storch A, Kaftan A, Burkhardt K, Schwarz J (2000) 6-Hydroxydopamine toxicity towards human SH-SY5Y dopaminergic neuroblastoma cells: independent of mitochondrial energy metabolism. J Neural Transm 107:281-293.
51. Wooten GF (1997) Neurochemistry and neuropharmacology of Parkinson's disease. In: Movement disorders: neurologic principles and practice (Watts RL, Koller WC, eds), pp 153-160. New York: McGraw-Hill.
52. Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, Mizuno Y (1996) Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci USA 93:2696-2701.